FranceFrance

Mutabilis Raises 8 Million Euros

10.07.2004

Paris - French drug discovery company Mutabilis S.A. closed an Euro8 million series B financing in mid-June with Auriga Partners as lead investor. The capital will provide sufficient financing to continue drug discovery activities until 2007, according to the company. Mutabilis develops new anti-infective molecules, that target virulence determinants on the surface of pathogenic bacteria which are multiresistent to current antibiotics.
“The new financing will allow Mutabilis to develop new chemical entities and to demonstrate that these molecules work in animals. By targeting just the bacteria responsible for an infection while leaving unharmed the intestinal flora and bacteria living in natural sites, Mutabilis' technology aims at allowing widespread use of anti-infective agents in situations where physicians today cannot use antibiotics because due the development of bacterial resistance”, explains Stéphane Huguet, CEO of Mutabilis. Clinical trials are expected to start in 2006.

FranceFrance

19.08.2011

Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...

FranceFrance

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...

FranceFrance

10.08.2011

Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....

FranceFrance

20.07.2011

Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...

FranceFrance

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...

FranceFrance

05.07.2011

French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...

FranceFrance

14.06.2011

Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/2/article/mutabilis-raises-8-million-euros.html

Product of the week

Products

Events

All Events

Current issue

All issues